Cationic Lipids with Hydrazide Groups for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering nucleic acids, such as siRNA and mRNA, face challenges including stability issues, susceptibility to nucleases, and limited ability to cross the cell membrane, particularly for immune cells like T cells and B-cells.
Innovation Solution
Development of novel cationic lipids with specific functional groups, such as hydrazine, hydroxylamine, and hydrazide, linked to fatty acid residues, which form lipid nanoparticles that protect nucleic acids, facilitate cellular uptake, and enhance endosomal escape.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If cationic lipids are used to deliver nucleic acids, then cellular uptake is facilitated, but stability against nucleases is insufficient
Solution Approach 1:
The patent employs composite lipid structures combining cationic head groups with specific fatty acid residues (containing hydrazine, hydroxylamine, or hydrazide functional groups) to create lipid nanoparticles that simultaneously achieve cellular uptake facilitation and nuclease resistance. The composite structure integrates multiple functional components within a single molecular architecture.
Solution Approach 2:
The invention modifies the chemical parameters of the lipid molecules by incorporating specific functional groups (hydrazine, hydroxylamine, hydrazide) linked to fatty acid residues with 10-22 carbons. These parameter changes in molecular structure confer enhanced stability while maintaining delivery efficacy.
2Productivity
If nucleic acids are delivered therapeutically, then gene therapy effects are achieved, but susceptibility to degradation occurs
Solution Approach 1:
The cationic lipid nanoparticles serve as intermediary carriers that protect nucleic acids from degradation by nucleases in the biological environment. The lipid structure acts as a protective medium that facilitates nucleic acid delivery while shielding it from harmful enzymatic degradation.
Solution Approach 2:
The patent creates composite lipid-nucleic acid complexes where the specially designed cationic lipids with functional groups form stable complexes with nucleic acids, protecting them from degradation while maintaining their therapeutic function.
3Ease of operation
If cell membrane crossing is enhanced, then intracellular delivery is improved, but toxicity increases
Solution Approach 1:
The patent applies local quality by designing lipids with specific functional groups (hydrazine, hydroxylamine, hydrazide) at particular positions in the molecular structure. This localized functionalization enables selective interaction with cell membranes and endosomal structures to facilitate intracellular delivery while controlling toxicity through precise structural design.
Solution Approach 2:
The invention optimizes the balance between delivery efficiency and toxicity by carefully selecting fatty acid residue lengths (10-22 carbons) and functional group types, thereby adjusting the physical and chemical parameters of the lipid molecules to achieve therapeutic windows.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel cationic lipids and lipid nanoparticles effectively protect nucleic acids from degradation, ensure intracellular delivery, and provide a therapeutic index that allows for effective dosing without unacceptable toxicity.
Implementation Method 1
Lipid nanoparticles formed from cationic lipids and other co-lipids such as cholesterol, DSPC and PEGylated lipids encapsulated oligonucleotides which protect them from degradation
Implementation Method 2
Cationic lipids have proved to be excellent carriers of nucleic acids... facilitate the cellular uptake
Implementation Method 3
enhance endosomal escape... ensure intracellular delivery
Data Source
AI summary
The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.